HC Berlin Pharma AG
HC Berlin Pharma AG filed patent for an innovative anti-aging remedy and moved into its own building in Potsdam-Golm
HC Berlin Pharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Berlin, June 8, 2009 - HC Berlin Pharma AG, listed on the Open Market of the Frankfurt Stock Exchange, announced that it has developed a new type of artemisinin based treatment for the anti-aging segment in a project with the Ernst-Moritz-Arndt University of Greifswald. HC Berlin Pharma AG's 'Life Science' research section, headed by Professor Dr. Hans-Peter Welzel, undertook experiments with the Pharmaceutics Institute of Ernst-Moritz-Arndt University of Greifswald in respect of the anti-aging properties of the artemisia annua (sweet wormwood) biomass - whose anti-malarial properties are already exploited with success. During the studies, some of the artemisia extracts produced showed a high capacity for catching free radicals - which was confirmed in tests with cell cultures. The research group has now developed a new type of treatment for reducing wrinkles which can be used in both the cosmetics and dermatology fields. HC Berlin Pharma AG and the Ernst-Moritz-Arndt University of Greifswald have applied for two patents in this regard with the German Patent and Trade Mark Office for the production and application of tenside-free emulsions with anti-aging effects as well as preparations of artemisia annua, their transformation into micro- and nano-particles and their applications. Patent ownership will be shared 49 % with HC Berlin Pharma AG and 51 % with the Ernst-Moritz-Arndt University of Greifswald. 'These product developments and patent applications, supported by the State of Brandenburg's Investment Bank (ILB) represent an important milestone for our company', Ottmar W. Geiger, CEO of HC Berlin Pharma AG, explained. 'Our innovative anti-aging product is proven to work against skin damaging free radicals and stops the skin's oxidization process. The necessary trials also have to be conducted for the accreditation of cosmetic binders based on the patented experimental results. After that the development of marketable products can follow', Geiger continued. 'Furthermore, we are very happy to have moved our headquarters - under retention of the legal seat of the Company in Berlin - to Professor Dr. Hasso Plattner's 17,000 m2, EUR 27.5m building in Potsdam Golm', Rudolf W. Schötteldreier, Chairman of HC Berlin Pharma AG's Supervisory Board, added. 'The 'Life Science' research section, under Professor Dr. Hans-Peter Welzel's leadership, has also moved from the BioInkubator GO:IN, to our new location at 'Am Mühlenberg 3'', Schötteldreier concluded. More information concerning HC Berlin Pharma AG can be found at www.hcberlinpharma.ag. For more detailed information please directly contact our Investor Relations Team: esVedra consulting GmbH t: +49. 89. 28 80 81 33 f: +49. 89. 28 80 81 49 info@esvedra-consulting.com www.esvedra-consulting.com About HC Berlin Pharma AG HC Berlin Pharma AG is a pharmaceutical company listed on the Open Market of the Frankfurt Stock Exchange, which develops and will manufacture pharmaceutical and high-tech medical technology solutions at its headquarters in Berlin. The company founded in May 2007 develops new pharmaceutical forms of already tried and tested substances which guarantee higher efficiency and healing capacity. The flagship product of HC Berlin Pharma AG is ArTiMist(TM), a sublingual spray for malaria treatment, especially designed for infants and children. With NiCoSorb(TM), a nicotine replacement therapy, HC Berlin Pharma AG develops another sublingual spray. In the field of medical technology HC Berlin Pharma AG in collaboration with Eastland Medical Systems Ltd offers safe injection syringes, ClipOn(TM) and VetLok(TM), for human and veterinary medicine as well as tamper evident and childproof medicinal packaging. Disclaimer This release only serves general purposes and is by no means intended as an invitation to buy or sell shares of HC Berlin Pharma AG. 08.06.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found